Drug
Nnc0487 0111
Nnc0487 0111: highest development phase Phase 3, developed by Novo Nordisk. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Novo Nordisk
Trials
| Drug | Phase | Indication |
|---|---|---|
| NNC0487-0111 NCT07571109 | Phase 3 | Obesity |
| NNC0487-0111 NCT07533175 | Phase 3 | Diabetes Mellitus |
| NNC0487-0111 NCT07400107 | Phase 3 | Obesity |
| NNC0487-0111 NCT07587710 | Phase 1 | Overweight |
Latest
No recent events.
Follow Nnc0487 0111 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.